Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Activation of the cAMP-generating system by vasoactive intestinal polypeptide (VIP) in the human laryngeal malignant cell line HEp-2

Abstract

In the presence of 3-isobutyi-l-methylxanthine, VIP produced a dose-related (3×10−9−10−7 M) increase (g-fold) in cAMP production in isolated HEp-2 cells incubated at 15°C in KRP buffer. Among the peptides structurally related to VIP, including secretin (10−7 M), pancreatic glucagon (10−6 M), PHI, somatostatin-14 (10−6 M), hpGRF (10−8−4×10−M), GIP (2×10−7 M), only PHI (3×10−7 M and above) is able to activate the cAMP-generating system in HEp-2 cells, but at 102 times lower potency. Under the same conditions, histamine (10−3 M) was also ineffective, while PGE 2 (10−7−10−4 M) increased (0-fold) basal cAMP levels in HEp-2 cells. The VIP effect is related to the interaction os the peptide on VIP recognition sites (12SI-VIP-binding capacity ), coupled to the membrane-bound adenylate cyclase . The results indicate that the transformed laryngeal cell line HEp-2 possessesa receptor-cAMP system preferentially activated by VIP (relative potencies: VIP > PHI ≫ other peptides of the secretin family), and suggest that this neuropeptide could modulate biological functions in normal laryngeal epithelia in man.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Said SI (1984) Peptides5, 143–150.

  2. 2.

    Laburthe M, Boissard C, Chevalier G, Zweibaum A & Rosselin G (1981) Regulatory Peptides2, 219–230.

  3. 3.

    Emami S, Gespach C, Forgue-Lafitte ME, Broer Y & Rosselin G (1983) Life Sci.33, 415–423.

  4. 4.

    Laburthe M, Rousset M, Chevalier G, Goissard C, Dupont C, Zweibaum A & Rosselin G (1980) Cancer Research40, 2529–2533.

  5. 5.

    Moore AEL, Sabachewsky L & Toolan HW (1955) Cancer Research15, 598–604.

  6. 6.

    Prost A, Emami S, Rosselin G & Gespach C (1984) Dig. Diseases and Sciences29, 66S.

  7. 7.

    Broer Y, Fouchereau M & Rosselin G (1972). C.R. Acad. Sci. Paris275, (D) 619–622.

  8. 8.

    Rosselin G & Freychet P (1973) Biochim. Biophys. Acta304, 541–551.

  9. 9.

    Tatemoto K & Mutt V (1980) Nature5764, 417–418.

  10. 10.

    Christophe J, Chatelain P, Taton G, Delhaye M, Waelbroeck M & Robberecht P (1981) Peptides2, 253–258.

  11. 11.

    Robberecht P, Chatelain P, De Neef P, Camus JC, Waelbroeck M & Christophe J (1981) Biochim. Biophys. Acta678, 76–82.

  12. 12.

    Watling KJ & Dowling JE (1983) J. Neurochem.41, 1205–1213.

  13. 13.

    Gespach C, Hui Bon Hoa D & Rosselin G (1983) Endocrinology, 1597–1606.

  14. 14.

    Christophe JP, Conlon TP & Gardner JD (1976) J. Biol. Chem.251, 4629–4634.

  15. 15.

    Gespach C, Emami S, Lhiaubet AM, Fournier A, St Pierre S, Rosselin G & Rostene W (1984) IRCS Med. Sci.12, 724–725.

  16. 16.

    Laburthe M, Amiranoff B, Boige N, Rouyer-Fessard C, Tatemoto K & Moroder L (1983) FEBS Lett.159, 89–92.

  17. 17.

    Laburthe M, Prieto JC, Amiranoff B, Dupont C, Hui Bon Hoa D & Rosselin G (1979) Eur J. Biochem.96, 239–248.

  18. 18.

    Gespach C, Bataille D, Dutrillaux MC & Rosselin G (1982) Biochim. Biophys. Acta720, 7–16.

  19. 19.

    Bataille D, Gespach C, Coudray AM and Rosselin G (1981) Biosci. Rep.1, 151–155.

  20. 20.

    Dubrasquet M, Bataille D & Gespach C (1982) Biosci. Rep.2, 391–395.

  21. 21.

    Bataille D, Tatemoto K, Gespach C, Jörnvall H, Rosselin G & Mutt V (1982) FEBS Lett.146, 79–86.

  22. 22.

    Depigny C, Lupo B, Kervran A & Bataille D (1984) Dig. Dis. Sciences29, 20S.

  23. 23.

    Dey RD, Shannon WA & Said SI (1981) Cell Tissue Res.220, 231–238.

  24. 24.

    Nathanson I, Widdicombe JH & Barnes PJ (1983) J. Appl. Physiol.55, 1844–1848.

  25. 25.

    Frandsen EK, Krishna GA & Said SI (1978) Brit. J. Pharmacol.62, 367–369.

Download references

Author information

Correspondence to Christian Gespach.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Prost, A., Emami, S., Rosselin, G. et al. Activation of the cAMP-generating system by vasoactive intestinal polypeptide (VIP) in the human laryngeal malignant cell line HEp-2. Biosci Rep 4, 1045–1050 (1984). https://doi.org/10.1007/BF01116697

Download citation

Keywords

  • Histamine
  • Glucagon
  • Adenylate Cyclase
  • Secretin
  • cAMP Level